CDKI-83
CDKI-83 is a potent CDK9 and CDK1 inhibitor with Ki values of 21 nM and 72 nM for CDK9/T1 and CDK1/B, respectively. CDKI-83 demonstrates effective anti-proliferative activity in human tumour cell lines with a GI50apoptosis in A2780 human ovarian cancer cells. CDKI-83 reduces phosphorylation at Ser-2 of RNA polymerase II (RNAPII) by inhibiting cellular CDK9 activity, and down-regulates Mcl-1 and Bcl-2. CDKI-83 has the potential for anti-cancer research[1].
Product Specifications
CAS Number
1189558-88-0
UNSPSC
12352005
Target
Apoptosis; Bcl-2 Family; CDK
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cdki-83.html
Smiles
N#CC1=CN=C(N=C1C2=C(N=C(S2)NC)C)NC3=CC=C(C(S(=O)(N4CCOCC4)=O)=C3)C
Molecular Formula
C21H23N7O3S2
Molecular Weight
485.58
References & Citations
[1]Xiangrui Liu, et al. In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83. Invest New Drugs. 2012 Jun;30 (3) :889-97.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK1; CDK2; CDK4; CDK7; CDK9
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
